相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2020
DIABETES CARE (2020)
Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis
Yue Zhou et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map
Jianhong Zhu et al.
LANCET DIABETES & ENDOCRINOLOGY (2020)
A novel method for interpreting survival analysis data: description and test on three major clinical trials on cardiovascular prevention
Alessandro Mengozzi et al.
TRIALS (2020)
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
Thomas A. Zelniker et al.
CIRCULATION (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Thiazolidinediones: the Forgotten Diabetes Medications
Harold E. Lebovitz
CURRENT DIABETES REPORTS (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
Fahmida Alam et al.
SCIENTIFIC REPORTS (2019)
Role of adipocyte mitochondria in inflammation, lipemia and insulin sensitivity in humans: effects of pioglitazone treatment
X. Xie et al.
INTERNATIONAL JOURNAL OF OBESITY (2018)
Pioglitazone Induces Cardiomyocyte Apoptosis and Inhibits Cardiomyocyte Hypertrophy Via VEGFR-2 Signaling Pathway
Wenliang Zhong et al.
ARQUIVOS BRASILEIROS DE CARDIOLOGIA (2018)
Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone
Lawrence H. Young et al.
CIRCULATION (2018)
Role of Wnt4/β-catenin, Ang II/TGFβ, ACE2, NF-κB, and IL-18 in attenuating renal ischemia/reperfusion-induced injury in rats treated with Vit D and pioglitazone
Rabab M. Ali et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
Effect of pioglitazone on cardiometabolic profiles and safety in patients with type 2 diabetes undergoing percutaneous coronary artery intervention: a prospective, multicenter, randomized trial
Atsushi Tanaka et al.
HEART AND VESSELS (2018)
PPAR-gamma activation is associated with reduced liver ischemia-reperfusion injury and altered tissue-resident macrophages polarization in a mouse model
Ivan Linares et al.
PLOS ONE (2018)
PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation
Ekaterina Legchenko et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Mechanistic insights into the augmented effect of bone marrow mesenchymal stem cells and thiazolidinediones in streptozotocin-nicotinamide induced diabetic rats
Alaaeldin Ahmed Hamza et al.
SCIENTIFIC REPORTS (2018)
Effect of Pioglitazone in Combination with Moderate Dose Statin on Atherosclerotic Inflammation: Randomized Controlled Clinical Trial Using Serial FDG-PET/CT
Eun Ho Choo et al.
KOREAN CIRCULATION JOURNAL (2018)
Cardiovascular Outcomes in Patients With Previous Myocardial Infarction and Mild Diabetes Mellitus Following Treatment With Pioglitazone Reports of a Randomised Trial From The Japan Working Group for the Assessment Whether Pioglitazone Protects DM Patients Against Re-Infarction (PPAR Study)
Masanori Asakura et al.
ECLINICALMEDICINE (2018)
Pioglitazone Alleviates Cardiac Fibrosis and Inhibits Endothelial to Mesenchymal Transition Induced by Pressure Overload
Wen-Ying Wei et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
PPARγ agonist use and recurrence of atrial fibrillation after successful electrical cardioversion
Jun Gu et al.
HELLENIC JOURNAL OF CARDIOLOGY (2017)
SIRT3 inhibits Ang II-induced transdifferentiation of cardiac fibroblasts through β-catenin/PPAR-γ signaling
Xiaobin Guo et al.
LIFE SCIENCES (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Metformin effects on the heart and the cardiovascular system: A review of experimental and clinical data
L. Nesti et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2017)
Non-insulin anti-diabetic drugs: An update on pharmacological interactions
M. Ruscica et al.
PHARMACOLOGICAL RESEARCH (2017)
Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis
Hung-Wei Liao et al.
BMJ OPEN (2017)
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA. IT): a randomised, multicentre trial
Olga Vaccaro et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
PPARγ attenuates hypoxia-induced hypertrophic transcriptional pathways in the heart
Abubakr Chaudhry et al.
PULMONARY CIRCULATION (2017)
Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes
Geoffrey D. Clarke et al.
DIABETES CARE (2017)
Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials
Marit de Jong et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Pioglitazone attenuates atrial remodeling and vulnerability to atrial fibrillation in alloxan-induced diabetic rabbits
Changle Liu et al.
CARDIOVASCULAR THERAPEUTICS (2017)
Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
Muhammad Abdul-Ghani et al.
DIABETES CARE (2017)
PPARγ Links BMP2 and TGFβ1 Pathways in Vascular Smooth Muscle Cells, Regulating Cell Proliferation and Glucose Metabolism
Laurent Calvier et al.
CELL METABOLISM (2017)
Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis
Zhiwei Zhang et al.
BMC CARDIOVASCULAR DISORDERS (2017)
Translating MicroRNA Biology in Pulmonary Hypertension It Will Take More Than miR Words
Hyung J. Chun et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
Thiazolidinediones improve flow-mediated dilation: a meta-analysis of randomized clinical trials
Marko Stojanovic et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association
Biykem Bozkurt et al.
CIRCULATION (2016)
Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor
R. A. DeFronzo et al.
DIABETES OBESITY & METABOLISM (2016)
Effect of pioglitazone on the abrogated cardioprotective effect of ischemic preconditioning in hyperlipidemic rat heart
Dhiraj Mittal et al.
INDIAN JOURNAL OF PHARMACOLOGY (2016)
Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension
Arnica Behringer et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2016)
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
W. N. Kernan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Effect of Pioglitazone in Preventing In-Stent Restenosis after Percutaneous Coronary Intervention in Patients with Type 2 Diabetes: A Meta-Analysis
Shi-jie Zhao et al.
PLOS ONE (2016)
Activation of Peroxisome Proliferator-Activated Receptor gamma (PPAR gamma) Through NF-kappa B/Brg1 and TGF-beta(1) Pathways Attenuates Cardiac Remodeling in Pressure-Overloaded Rat Hearts
Han-Ping Qi et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2015)
Pioglitazone Increases Circulating MicroRNA-24 With Decrease in Coronary Neointimal Hyperplasia in Type 2 Diabetic Patients - Optical Coherence Tomography Analysis -
Soon Jun Hong et al.
CIRCULATION JOURNAL (2015)
Peroxisome Proliferator-activated Receptor-γ Agonist Pioglitazone Ameliorates White Matter Lesion and Cognitive Impairment in Hypertensive Rats
Lin-Fang Lan et al.
CNS NEUROSCIENCE & THERAPEUTICS (2015)
Pioglitazone Reduces Vascular Lipid Accumulation in Angiotensin II-Induced Hypertensive Rat
Aiko Sakamoto et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2015)
Pioglitazone treatment enhances the sympathetic nervous system response to oral carbohydrate load in obese individuals with metabolic syndrome
Nora E. Straznicky et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Smooth-muscle BMAL1 participates in blood pressure circadian rhythm regulation
Zhongwen Xie et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Pioglitazone reduces angiotensin II-induced COX-2 expression through inhibition of ROS production and ET-1 transcription in vascular cells from spontaneously hypertensive rats
Jose V. Perez-Giron et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2014)
Beneficial Effects of Pioglitazone on Retardation of Persistent Atrial Fibrillation Progression in Diabetes Mellitus Patients
Bing Liu et al.
INTERNATIONAL HEART JOURNAL (2014)
A Randomized Controlled Trial of the Effects of Pioglitazone Treatment on Sympathetic Nervous System Activity and Cardiovascular Function in Obese Subjects With Metabolic Syndrome
Nora E. Straznicky et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Effect of Pioglitazone on In-Stent Restenosis after Coronary Drug-Eluting Stent Implantation: A Meta-Analysis of Randomized Controlled Trials
Ming-duo Zhang et al.
PLOS ONE (2014)
Pioglitazone Improves Fat Distribution, the Adipokine Profile and Hepatic Insulin Sensitivity in Non-Diabetic End-Stage Renal Disease Subjects on Maintenance Dialysis: A Randomized Cross-Over Pilot Study
Anne Zanchi et al.
PLOS ONE (2014)
Effect of peroxisome proliferator-activated receptor gamma agonist on heart of rabbits with acute myocardial ischemia/reperfusion injury
Qian Hu et al.
ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE (2014)
Is Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) a Therapeutic Target for the Treatment of Pulmonary Hypertension?
David E. Green et al.
Pulmonary Circulation (2014)
Pioglitazone Improves Potassium Channel Remodeling Induced by Angiotensin II in Atrial Myocytes
Jun Gu et al.
MEDICAL SCIENCE MONITOR BASIC RESEARCH (2014)
Peroxisome proliferator-activated receptors for hypertension
Daisuke Usuda et al.
WORLD JOURNAL OF CARDIOLOGY (2014)
Suppression of Primary Aldosteronism and Resistant Hypertension by the Peroxisome Proliferator-activated Receptor Gamma Agonist Pioglitazone
Yusuke Kashiwagi et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2013)
Risk of Stroke with Thiazolidinediones: A Ten-Year Nationwide Population-Based Cohort Study
Chien-Jung Lu et al.
CEREBROVASCULAR DISEASES (2013)
Circadian-clock system in mouse liver affected by insulin resistance
Shu-Chuan Yang et al.
CHRONOBIOLOGY INTERNATIONAL (2013)
Role of the EGF receptor in PPARγ-mediated sodium and water transport in human proximal tubule cells
S. Saad et al.
DIABETOLOGIA (2013)
Effects of pioglitazone on cardiac ion currents and action potential morphology in canine ventricular myocytes
Kornel Kistamas et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
A randomized placebo controlled double blind crossover study of pioglitazone on left ventricular diastolic function in type 2 diabetes
Alun David Hughes et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Pioglitazone may offer therapeutic advantages in diabetes-related atrial fibrillation
Changle Liu et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Effects of Pioglitazone on Visceral Fat Metabolic Activity in Impaired Glucose Tolerance or Type 2 Diabetes Mellitus
Norihiro Kodama et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Beneficial effects of pioglitazone on atrial structural and electrical remodeling in vitro cellular models
Jun Gu et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2013)
Relaxation of human pulmonary arteries by PPARγ agonists
Hanna Kozlowska et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2013)
Rosiglitazone preserves pulmonary vascular function in lambs with increased pulmonary blood flow
Peter E. Oishi et al.
PEDIATRIC RESEARCH (2013)
Effects of Low Dose Pioglitazone on Restenosis and Coronary Atherosclerosis in Diabetic Patients Undergoing Drug Eluting Stent Implantation
Hye Won Lee et al.
YONSEI MEDICAL JOURNAL (2013)
Combined Effects of PPARγ Agonists and Epidermal Growth Factor Receptor Inhibitors in Human Proximal Tubule Cells
Katherine Pegg et al.
PPAR RESEARCH (2013)
Peroxisome Proliferator-Activated Receptor-γ in Capillary Endothelia Promotes Fatty Acid Uptake by Heart During Long-Term Fasting
Kosaku Goto et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2013)
The Peroxisome Proliferator Activated Receptor-γ Pioglitazone Improves Vascular Function and Decreases Disease Activity in Patients With Rheumatoid Arthritis
Wendy Marder et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2013)
Pioglitazone attenuates progression of aortic valve calcification via down-regulating receptor for advanced glycation end products
Fei Li et al.
BASIC RESEARCH IN CARDIOLOGY (2012)
Interaction Between NFκB and NFAT Coordinates Cardiac Hypertrophy and Pathological Remodeling
Qinghang Liu et al.
CIRCULATION RESEARCH (2012)
Reduction of renal lipid content and proteinuria by a PPAR-γ agonist in a rat model of angiotensin II-induced hypertension
Aiko Sakamoto et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2012)
Effects of Pioglitazone on High-Fat-Diet-Induced Ventricular Remodeling and Dysfunction in Rats
Ya-Qiang Tian et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2012)
Pioglitazone attenuates myocardial ischemia-reperfusion injury via up-regulation of ERK and COX-2
Hao Wang et al.
BIOSCIENCE TRENDS (2012)
Effect of pioglitazone on cardiac sympathovagal modulation in patients with type 2 diabetes
F. E. Gianiorio et al.
ACTA DIABETOLOGICA (2011)
Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects
Stefano Rizza et al.
ATHEROSCLEROSIS (2011)
Effect of Pretreatment With Pioglitazone on Reperfusion Injury in Diabetic Patients With Acute Myocardial Infarction
Yu Kataoka et al.
CIRCULATION JOURNAL (2011)
Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus
Jun Gu et al.
EUROPACE (2011)
Pharmacological preconditioning with nicorandil and pioglitazone attenuates myocardial ischemia/reperfusion injury in rats
Lamiaa A. Ahmed et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats
Osamu Kume et al.
HEART RHYTHM (2011)
Impact of insulin sensitivity treatment with pioglitazone on endothelial function in non-diabetic patients with arterial hypertension
F. Schneider et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Role of Pioglitazone in the Prevention of Restenosis and Need for Revascularization After Bare-Metal Stent Implantation A Meta-Analysis
Dhavalkumar Patel et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2011)
Pioglitazone Attenuates Atherosclerotic Plaque Inflammation in Patients With Impaired Glucose Tolerance or Diabetes A Prospective, Randomized, Comparator-Controlled Study Using Serial FDG PET/CT Imaging Study of Carotid Artery and Ascending Aorta
Minori Mizoguchi et al.
JACC-CARDIOVASCULAR IMAGING (2011)
Insulin Resistance, Obesity, Hypertension, and Renal Sodium Transport
Shoko Horita et al.
INTERNATIONAL JOURNAL OF HYPERTENSION (2011)
Cardiomyocyte-derived adiponectin is biologically active in protecting against myocardial ischemia-reperfusion injury
Yajing Wang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2010)
The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA
Yumei Ye et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2010)
Rosiglitazone Attenuates Chronic Hypoxia-Induced Pulmonary Hypertension in a Mouse Model
Rachel E. Nisbet et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2010)
Cellular and Molecular Changes Associated With Inhibitory Effect of Pioglitazone on Neointimal Growth in Patients With Type 2 Diabetes After Zotarolimus-Eluting Stent Implantation
Soon Jun Hong et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue doppler imaging study
Katerina K. Naka et al.
CARDIOVASCULAR DIABETOLOGY (2010)
Adiponectin An Indispensable Molecule in Rosiglitazone Cardioprotection Following Myocardial Infarction
Ling Tao et al.
CIRCULATION RESEARCH (2010)
Effect of pioglitazone on endothelial function in impaired glucose tolerance
C. E. Quinn et al.
DIABETES OBESITY & METABOLISM (2010)
Rosiglitazone, but Not Pioglitazone, Improves Myocardial Systolic Function in Type 2 Diabetic Patients: A Tissue Doppler Study
Selcuk Pala et al.
ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES (2010)
PPARγ-induced cardiolipotoxicity in mice is ameliorated by PPARα deficiency despite increases in fatty acid oxidation
Ni-Huiping Son et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Pioglitazone Increases the Proportion of Small Cells in Human Abdominal Subcutaneous Adipose Tissue
Tracey M. McLaughlin et al.
OBESITY (2010)
The PPARβ/δAgonist GW0742 Relaxes Pulmonary Vessels and Limits Right Heart Hypertrophy in Rats with Hypoxia-Induced Pulmonary Hypertension
Louise S. Harrington et al.
PLOS ONE (2010)
Rosiglitazone attenuates hypoxia-induced pulmonary arterial hypertension in rats
Eun Kyung Kim et al.
RESPIROLOGY (2010)
PPARs and the Cardiovascular System
Milton Hamblin et al.
ANTIOXIDANTS & REDOX SIGNALING (2009)
Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes
Katerina Papathanassiou et al.
ATHEROSCLEROSIS (2009)
Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes
Mozhgan Dorkhan et al.
CARDIOVASCULAR DIABETOLOGY (2009)
A potential link between peroxisome proliferator-activated receptor signalling and the pathogenesis of arrhythmogenic right ventricular cardiomyopathy
Fatima Djouadi et al.
CARDIOVASCULAR RESEARCH (2009)
Pioglitazone Improves Cardiac Function and Alters Myocardial Substrate Metabolism Without Affecting Cardiac Triglyceride Accumulation and High-Energy Phosphate Metabolism in Patients With Well-Controlled Type 2 Diabetes Mellitus
Rutger W. van der Meer et al.
CIRCULATION (2009)
A Prospective, Multicenter, Randomized Trial to Assess Efficacy of Pioglitazone on In-Stent Neointimal Suppression in Type 2 Diabetes POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study)
Tsutomu Takagi et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2009)
Effect of pioglitazone on left ventricular diastolic function and fibrosis of type III collagen in type 2 diabetic patients
Gen Terui et al.
JOURNAL OF CARDIOLOGY (2009)
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Philip D. Home et al.
LANCET (2009)
The role of Sgk-1 in the upregulation of transport proteins by PPAR-γ agonists in human proximal tubule cells
Sonia Saad et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice
Yumei Ye et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2008)
Pioglitazone induces lipid accumulation in the rat heart despite concomitant reduction in plasma free fatty acid availability
Marcin Baranowski et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2008)
Vascular PPARγ Controls Circadian Variation in Blood Pressure and Heart Rate through Bmal1
Ningning Wang et al.
CELL METABOLISM (2008)
Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus
Michael Davidson et al.
CIRCULATION (2008)
Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor γ in cardiac fibrosis
Evren Caglayan et al.
DIABETES (2008)
Differences in effects of insulin glargine or pioglitazone added to oral anti-diabetic therapy in patients with type 2 diabetes What to add-Insulin glargine or pioglitazone?
Mozhgan Dorkhan et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2008)
Pioglitazone, a thiazolidinedione derivative, attenuates left ventricular hypertrophy and fibrosis in salt-sensitive hypertension
Minori Nakamoto et al.
HYPERTENSION RESEARCH (2008)
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes -: The PERISCOPE randomized controlled trial
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
The PPAR trio: Regulators of myocardial energy metabolism in health and disease
Jose A. Madrazo et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2008)
Renal cytochrome P450 as a determinant of impaired natriuresis by PPAR-γ ligands in ovariectomized obese rats
Kyoko Yoshioka et al.
OBESITY (2008)
Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure
Erland Erdmann et al.
EUROPEAN HEART JOURNAL (2008)
Diverse cardioprotective signaling mechanisms of peroxisome proliferator-activated receptor-γ ligands, 15-deoxy-Δ12,14-prostaglandin j2 and ciglitazone, in reperfusion injury:: Role of nuclear factor-κB, heat shock factor 1, and Akt
Basilia Zingarelli et al.
SHOCK (2007)
Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08)
Erland Erdmann et al.
DIABETES CARE (2007)
Cardiac peroxisome proliferator-activated receptor γ is essential in protecting cardiomyocytes from oxidative damage
Guoliang Ding et al.
CARDIOVASCULAR RESEARCH (2007)
Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus
Tetsuya Teranishi et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2007)
Cardiomyocyte expression of PPARγ leads to cardiac dysfunction in mice
Ni-Huiping Son et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials
Rodrigo M. Lago et al.
LANCET (2007)
Pioglitazone shift circadian rhythm of blood pressure from non-dipper to dipper type in type 2 diabetes mellitus
F. Anan et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2007)
The insulin sensitizer pioglitazone improves the deterioration of ischemic preconditioning in type 2 diabetes Mellitus rats
Hideki Sasaki et al.
INTERNATIONAL HEART JOURNAL (2007)
Beneficial effects of pioglitazone on left ventricular hypertrophy in genetically hypertensive rats
Tomoko Shinzato et al.
HYPERTENSION RESEARCH (2007)
Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin
Giuseppe Derosa et al.
HYPERTENSION RESEARCH (2007)
Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling
Joseph T. Crossno et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2007)
Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-γ activation
Georg Hansmann et al.
CIRCULATION (2007)
Pioglitazone induces de novo ceramide synthesis in the rat heart
Marcin Baranowski et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2007)
Effect of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on ischemia-reperfusion injury in rats
Zeling Cao et al.
PHARMACOLOGY (2007)
The IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight
T. Schoendorf et al.
DIABETES OBESITY & METABOLISM (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes - A randomized trial
Theodore Mazzone et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions
Yumei Ye et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Pioglitazone prevents cardiac remodeling in high-fat, high-calorie-induced Type 2 diabetes mellitus
Walter E. Rodriguez et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Suppression of canonical Wnt/β-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy
Eduardo Garcia-Gras et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Phenotypic plasticity of adult myocardium: molecular mechanisms
Bernard Swynghedauw
JOURNAL OF EXPERIMENTAL BIOLOGY (2006)
Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes
H Sourij et al.
DIABETES CARE (2006)
Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: A multicenter, randomized, double-blind, controlled clinical trial
Giuseppe Derosa et al.
CLINICAL THERAPEUTICS (2006)
Rosiglitazone regulates ENaC and Na-K-2Cl cotransporter (NKCC2) abundance in the obese Zucker rat
Shahla Riazi et al.
AMERICAN JOURNAL OF NEPHROLOGY (2006)
Peroxisome proliferator-activated receptor-gamma ligands attenuate brain natriuretic peptide production and affect remodeling in cardiac fibroblasts in reoxygenation after hypoxia
Naoki Makino et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2006)
Kidney-specific gene targeting: Insight into thiazolidinedione-induced fluid retention
Tianxin Yang
NEPHROLOGY (2006)
Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes
FMAC Martens et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2005)
Rhythmic messenger ribonucleic acid expression of clock genes and adipocytokines in mouse visceral adipose tissue
H Ando et al.
ENDOCRINOLOGY (2005)
Pioglitazone reduces neointima volume after coronary stent implantation -: A randomized, placebo-controlled, double-blind trial in nondiabetic patients
N Marx et al.
CIRCULATION (2005)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease -: A 16-week randomized, double-blind, placebo-controlled study
R Lautamäki et al.
DIABETES (2005)
Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-γ both induce cardiac hypertrophy in mice
SZ Duan et al.
CIRCULATION RESEARCH (2005)
Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption
YF Guan et al.
NATURE MEDICINE (2005)
Pioglitazone improves left ventricular diastolic function in patients with essential hypertension
T Horio et al.
AMERICAN JOURNAL OF HYPERTENSION (2005)
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
RB Goldberg et al.
DIABETES CARE (2005)
Characterization of plasma brain natriuretic peptide level in patients with type 2 diabetes
M Igarashi et al.
ENDOCRINE JOURNAL (2005)
Peroxisome proliferator-activated receptor agonists modulate heart function in transgenic mice with lipotoxic cardiomyopathy
RK Vikramadithyan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo
I Bogacka et al.
DIABETES (2005)
PPAR-gamma modulates allergic inflammation through upregulation of PTEN
KS Lee et al.
FASEB JOURNAL (2005)
Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial
SR Smith et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2005)
Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects
A Hammarstedt et al.
DIABETOLOGIA (2005)
Effects of the peroxisomal proliferator-activated receptor-γ agonist pioglitazone on renal and hormonal responses to salt in healthy men
A Zanchi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats
J Song et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
The effect of pioglitazone on peroxisome proliferator-activated receptor-γ target genes related to lipid storage in vivo
I Bogacka et al.
DIABETES CARE (2004)
Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone
K Hällsten et al.
DIABETIC MEDICINE (2004)
Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo -: A study using the novel PPARα/γ agonist tesaglitazar
BD Hegarty et al.
ENDOCRINOLOGY (2004)
Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity
AD Dobrian et al.
HYPERTENSION (2004)
Thiazolidinediones reduces endothelial expression of receptors for advanced glycation end products
N Marx et al.
DIABETES (2004)
Considerations for management of fluid dynamic issues associated with thiazolidinediones
NK Hollenberg
AMERICAN JOURNAL OF MEDICINE (2003)
Effects of a PPARγ agonist, GI262570, on renal filtration fraction and nitric oxide level in conscious rats
BC Yang et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2003)
Rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-γ (PPAR-γ), reduce ischaemia/reperfusion injury of the gut
S Cuzzocrea et al.
BRITISH JOURNAL OF PHARMACOLOGY (2003)
Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone
S Ogawa et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Peroxisome proliferator-activated receptor gamma (PPARγ) expression is decreased in pulmonary hypertension and affects endothelial cell growth
S Ameshima et al.
CIRCULATION RESEARCH (2003)
Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity
S Shadid et al.
DIABETES CARE (2003)
Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model
SK Kim et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2003)
Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction
T Shiomi et al.
CIRCULATION (2002)
Ligands of the peroxisome proliferator-activated receptors (PPAR-γ and PPAR-α) reduce myocardial infarct size
NS Wayman et al.
FASEB JOURNAL (2002)
Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro
A Galli et al.
GASTROENTEROLOGY (2002)
Peroxisome proliferator-activated receptor γ plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo
M Asakawa et al.
CIRCULATION (2002)
Thiazolidinediones enhance insulin-mediated suppression of fatty acid flux in type 2 diabetes mellitus
SB Racette et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2002)
Peroxisome proliferator-activated receptor γ inhibits transforming growth factor β-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3
MG Fu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Peroxisome proliferator-activated receptor γ activators inhibit cardiac hypertrophy in cardiac myocytes
K Yamamoto et al.
CIRCULATION (2001)
Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance
CJ de Souza et al.
DIABETES (2001)
Lessons from the glitazones: a story of drug development
EAM Gale
LANCET (2001)
The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients
T Baba et al.
DIABETES CARE (2001)
Lipid lowering explains the insulin sensitivity enhancing effects of a thiazolidinedione, 5-(4-(2-(2-phenyl-4-oxazolyl)ethoxy)benzyl)-2,4 thiazolidinedione
FE Yakubu-Madus et al.
DIABETES OBESITY & METABOLISM (2000)
Lipotoxic heart disease in obese rats: Implications for human obesity
YT Zhou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
